Abstract：Objective To explore the high-risk factors and analyze the clinical characteristics of massive pulmonary hemorrhage (MPH) in infants with extremely low birth weight (ELBW). Methods Two hundred and eleven ELBW infants were included in this study. Thirty-five ELBW infants who were diagnosed with MPH were labelled as the MPH group, and 176 ELBW infants without pulmonary hemorrhage were labelled as the control group. The differences in clinical characteristics, mortality rate, and incidence of complications between the two groups were analysed. The high-risk factors for MPH were identified by multiple logistic regression analysis. Results The MPH group had significantly lower gestational age, birth weight, and 5-minute Apgar score than the control group (P < 0.05). The MPH group had significantly higher rates of neonatal respiratory distress syndrome, patent ductus arteriosus (PDA), early-onset sepsis (EOS), intracranial hemorrhage, pulmonary surfactant utilization, and death compared with the control group (P < 0.01). The multiple logistic regression analysis showed that 5-minute Apgar score was a protective factor for MPH (OR=0.666, P < 0.05), and that PDA and EOS were risk factors for MPH (OR=3.717, 3.276 respectively; P < 0.01). In the infants who were discharged normally, the MPH group had a longer duration of auxiliary ventilation and a higher incidence rate of ventilator-associated pneumonia (VAP) compared with the control group (P < 0.05). Conclusions A higher 5-minute Apgar score is associated a decreased risk for MPH, and the prensence of PDA or EOS is associated an increased risk for MPH in ELBW infants. ELBW infants with MPH have a prolonged mechanical ventilation, a higher mortality, and higher incidence rates of VAP and intracranial hemorrhage compared with those without pulmonary hemorrhage.
Lin TW, Su BH, Lin HC, et al. Risk factors of pulmonary hemorrhage in very-low-birth-weight infants:a two-year retrospective study[J]. Acta Paediatr Taiwan, 2000, 41(5):255-258.
[2]
Kluckow M, Evans N. Ductal shunting, high pulmonary blood flow, and pulmonary hemorrhage[J]. J Pediatr, 2000, 137(1):68-72.
[3]
Chen YY, Wang HP, Lin SM, et al. Pulmonary hemorrhage in very low-birthweight infants:risk factors and management[J]. Pediatr Int, 2012, 54(6):743-747.
[4]
Zahr RA, Ashfaq A, Marron-Corwin M. Neonatal pulmonary hemorrhage[J]. Neo Reviews, 2012, 13(5):302-306.
[5]
Aziz A, Ohlsson A. Surfactant for pulmonary haemorrhage in neonates[J]. Cochrane Database Syst Rev, 2012, (7):CD005254.
[6]
Ringer SA. Care of the extremely low birth weight infant[M]//Cloherty JP, Eichenwald EC, Hansen AR, et al. Manual of Neonatal Care. 7th ed. Philadelphia:Lippincott Williams & Willkins, 2011:154-165.
Ferreira CH, Carmona F, Martinez FE. Prevalence, risk factors and outcomes associated with pulmonary hemorrhage in newborns[J]. J Pediatr (Rio J), 2014, 90(3):316-322.
[9]
Hansen TN, Corbet A. Pulmonary physiology of the newborn[M]//Taeusch HW, Ballard RA, Gleason CA, et al. Avery's Diseases of the Newborn. 8th ed. Philadelphia:Saunders, 2005:634-647.
[10]
Kluckow M, Jeffery M, Gill A, et al. A randomised placebo-controlled trial of early treatment of the patent ductus arteriosus[J]. Arch Dis Child Fetal Neonatal Ed, 2014, 99(2):F99-F104.
[11]
Scholl JE, Yanowitz TD. Pulmonary hemorrhage in very low birth weight infants:a case-control analysis[J]. J Pediatr, 2015, 166(4):1083-1084.
[12]
Pandit PB, O'Brien K, Asztalos E, et al. Outcome following pulmonary haemorrhage in very low birthweight neonates treated with surfactant[J]. Arch Dis Child Fetal Neonatal Ed, 1999, 81(1):F40-F44.
[13]
Tsou KI, Tsao PN, Taiwan Infant Development Collaborative Study Group. The morbidity and survival of very-low-birth-weight infants in Taiwan[J]. Acta Paediatr Taiwan, 2003, 44(6):349-355.
